S&P 500   3,273.40 (-0.09%)
DOW   28,734.45 (+0.04%)
QQQ   221.81 (+0.16%)
FB   223.23 (+2.50%)
MSFT   168.04 (+1.56%)
GOOGL   1,456.70 (+0.43%)
AMZN   1,858.00 (+0.26%)
CGC   23.52 (-1.67%)
NVDA   245.54 (-0.98%)
BABA   212.09 (+0.88%)
MU   55.30 (-2.07%)
GE   12.94 (+10.32%)
TSLA   580.99 (+2.49%)
AMD   47.51 (-5.98%)
T   37.04 (-3.99%)
NFLX   343.16 (-1.54%)
BAC   33.01 (-0.69%)
DIS   136.07 (-1.66%)
GILD   64.30 (-0.09%)
S&P 500   3,273.40 (-0.09%)
DOW   28,734.45 (+0.04%)
QQQ   221.81 (+0.16%)
FB   223.23 (+2.50%)
MSFT   168.04 (+1.56%)
GOOGL   1,456.70 (+0.43%)
AMZN   1,858.00 (+0.26%)
CGC   23.52 (-1.67%)
NVDA   245.54 (-0.98%)
BABA   212.09 (+0.88%)
MU   55.30 (-2.07%)
GE   12.94 (+10.32%)
TSLA   580.99 (+2.49%)
AMD   47.51 (-5.98%)
T   37.04 (-3.99%)
NFLX   343.16 (-1.54%)
BAC   33.01 (-0.69%)
DIS   136.07 (-1.66%)
GILD   64.30 (-0.09%)
S&P 500   3,273.40 (-0.09%)
DOW   28,734.45 (+0.04%)
QQQ   221.81 (+0.16%)
FB   223.23 (+2.50%)
MSFT   168.04 (+1.56%)
GOOGL   1,456.70 (+0.43%)
AMZN   1,858.00 (+0.26%)
CGC   23.52 (-1.67%)
NVDA   245.54 (-0.98%)
BABA   212.09 (+0.88%)
MU   55.30 (-2.07%)
GE   12.94 (+10.32%)
TSLA   580.99 (+2.49%)
AMD   47.51 (-5.98%)
T   37.04 (-3.99%)
NFLX   343.16 (-1.54%)
BAC   33.01 (-0.69%)
DIS   136.07 (-1.66%)
GILD   64.30 (-0.09%)
S&P 500   3,273.40 (-0.09%)
DOW   28,734.45 (+0.04%)
QQQ   221.81 (+0.16%)
FB   223.23 (+2.50%)
MSFT   168.04 (+1.56%)
GOOGL   1,456.70 (+0.43%)
AMZN   1,858.00 (+0.26%)
CGC   23.52 (-1.67%)
NVDA   245.54 (-0.98%)
BABA   212.09 (+0.88%)
MU   55.30 (-2.07%)
GE   12.94 (+10.32%)
TSLA   580.99 (+2.49%)
AMD   47.51 (-5.98%)
T   37.04 (-3.99%)
NFLX   343.16 (-1.54%)
BAC   33.01 (-0.69%)
DIS   136.07 (-1.66%)
GILD   64.30 (-0.09%)
Log in

NASDAQ:SAGE - SAGE Therapeutics Stock Price, Forecast & News

$68.66
+0.02 (+0.03 %)
(As of 01/29/2020 04:00 PM ET)
Today's Range
$68.38
Now: $68.66
$69.25
50-Day Range
$63.24
MA: $73.24
$77.24
52-Week Range
$56.50
Now: $68.66
$193.56
Volume463,178 shs
Average Volume783,596 shs
Market Capitalization$3.56 billion
P/E RatioN/A
Dividend YieldN/A
Beta2.32
Sage Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel medicines to treat central nervous system (CNS) disorders. Its lead product candidate is ZULRESSO, a proprietary intravenous formulation of brexanolone that has completed Phase III clinical trials for the treatment of postpartum depression (PPD). The company's product pipeline also includes SAGE-217, a novel neuroactive steroid, which is in Phase III clinical trials for treating PPD, major depressive disorders, bipolar depression, and sleep disorders; and SAGE-324, a novel neuroactive steroid that has completed Phase I clinical trials to treat various neurological conditions, including essential tremor and epileptiform disorders. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:SAGE
CUSIPN/A
Phone617-299-8380

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$90.27 million
Book Value$18.41 per share

Profitability

Net Income$-372,880,000.00
Net Margins-12,931.34%

Miscellaneous

Employees637
Market Cap$3.56 billion
Next Earnings Date2/18/2020 (Estimated)
OptionableOptionable

Receive SAGE News and Ratings via Email

Sign-up to receive the latest news and ratings for SAGE and its competitors with MarketBeat's FREE daily newsletter.


SAGE Therapeutics (NASDAQ:SAGE) Frequently Asked Questions

What is SAGE Therapeutics' stock symbol?

SAGE Therapeutics trades on the NASDAQ under the ticker symbol "SAGE."

How were SAGE Therapeutics' earnings last quarter?

SAGE Therapeutics Inc (NASDAQ:SAGE) posted its quarterly earnings results on Tuesday, November, 12th. The biopharmaceutical company reported ($3.48) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($3.41) by $0.07. The biopharmaceutical company had revenue of $3.57 million for the quarter, compared to the consensus estimate of $2.52 million. SAGE Therapeutics had a negative net margin of 12,931.34% and a negative return on equity of 60.00%. SAGE Therapeutics's quarterly revenue was up 35600.0% compared to the same quarter last year. During the same quarter in the previous year, the company posted ($2.63) EPS. View SAGE Therapeutics' Earnings History.

When is SAGE Therapeutics' next earnings date?

SAGE Therapeutics is scheduled to release their next quarterly earnings announcement on Tuesday, February 18th 2020. View Earnings Estimates for SAGE Therapeutics.

What price target have analysts set for SAGE?

19 analysts have issued 1 year target prices for SAGE Therapeutics' stock. Their forecasts range from $63.00 to $263.00. On average, they anticipate SAGE Therapeutics' share price to reach $127.00 in the next twelve months. This suggests a possible upside of 85.0% from the stock's current price. View Analyst Price Targets for SAGE Therapeutics.

What is the consensus analysts' recommendation for SAGE Therapeutics?

19 Wall Street analysts have issued "buy," "hold," and "sell" ratings for SAGE Therapeutics in the last year. There are currently 6 hold ratings and 13 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for SAGE Therapeutics.

Has SAGE Therapeutics been receiving favorable news coverage?

News stories about SAGE stock have trended very positive recently, InfoTrie reports. The research firm rates the sentiment of media coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. SAGE Therapeutics earned a news sentiment score of 3.3 on InfoTrie's scale. They also assigned media headlines about the biopharmaceutical company a news buzz of 2.0 out of 10, meaning that recent media coverage is very unlikely to have an impact on the company's share price in the immediate future. View News Stories for SAGE Therapeutics.

Are investors shorting SAGE Therapeutics?

SAGE Therapeutics saw a increase in short interest during the month of January. As of January 15th, there was short interest totalling 7,050,000 shares, an increase of 15.6% from the December 31st total of 6,100,000 shares. Based on an average daily volume of 1,070,000 shares, the days-to-cover ratio is presently 6.6 days. Currently, 13.9% of the company's stock are sold short. View SAGE Therapeutics' Current Options Chain.

Who are some of SAGE Therapeutics' key competitors?

What other stocks do shareholders of SAGE Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other SAGE Therapeutics investors own include NVIDIA (NVDA), Alibaba Group (BABA), Micron Technology (MU), AbbVie (ABBV), Netflix (NFLX), Intercept Pharmaceuticals (ICPT), Advanced Micro Devices (AMD), GW Pharmaceuticals PLC- (GWPH), salesforce.com (CRM) and Twitter (TWTR).

Who are SAGE Therapeutics' key executives?

SAGE Therapeutics' management team includes the folowing people:
  • Dr. Jeffrey M. Jonas, CEO, Pres & Director (Age 66)
  • Ms. Kimi E. Iguchi, CFO & Treasurer (Age 57)
  • Dr. Albert J. Robichaud, Chief Scientific Officer (Age 58)
  • Ms. Anne Marie Cook, Sr. VP, Gen. Counsel & Sec. (Age 57)
  • Mr. Michael Cloonan, Chief Bus. Officer (Age 48)

Who are SAGE Therapeutics' major shareholders?

SAGE Therapeutics' stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include California Public Employees Retirement System (0.22%), Columbus Circle Investors (0.18%), Strs Ohio (0.10%), Rhenman & Partners Asset Management AB (0.10%), Clarius Group LLC (0.07%) and EFG Asset Management Americas Corp. (0.06%). Company insiders that own SAGE Therapeutics stock include Albert Robichaud, Anne Marie Cook, James M Frates, Jeffrey M Jonas, Kevin P Starr, Kimi Iguchi, Michael Cloonan, Stephen Kanes and Steven M Paul. View Institutional Ownership Trends for SAGE Therapeutics.

Which major investors are selling SAGE Therapeutics stock?

SAGE stock was sold by a variety of institutional investors in the last quarter, including Tocqueville Asset Management L.P., Strs Ohio, Nisa Investment Advisors LLC, Columbus Circle Investors and Arthur M. Cohen & Associates LLC. Company insiders that have sold SAGE Therapeutics company stock in the last year include Anne Marie Cook, James M Frates, Jeffrey M Jonas, Kimi Iguchi, Michael Cloonan, Stephen Kanes and Steven M Paul. View Insider Buying and Selling for SAGE Therapeutics.

Which major investors are buying SAGE Therapeutics stock?

SAGE stock was purchased by a variety of institutional investors in the last quarter, including Clarius Group LLC, Rhenman & Partners Asset Management AB, California Public Employees Retirement System, Aurora Investment Managers LLC., EFG Asset Management Americas Corp., Landsberg Bennett & Dubbaneh LLC, Alpine Global Management LLC and Chartwell Investment Partners LLC. Company insiders that have bought SAGE Therapeutics stock in the last two years include Albert Robichaud and Jeffrey M Jonas. View Insider Buying and Selling for SAGE Therapeutics.

How do I buy shares of SAGE Therapeutics?

Shares of SAGE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is SAGE Therapeutics' stock price today?

One share of SAGE stock can currently be purchased for approximately $68.66.

How big of a company is SAGE Therapeutics?

SAGE Therapeutics has a market capitalization of $3.56 billion and generates $90.27 million in revenue each year. The biopharmaceutical company earns $-372,880,000.00 in net income (profit) each year or ($8.08) on an earnings per share basis. SAGE Therapeutics employs 637 workers across the globe.View Additional Information About SAGE Therapeutics.

What is SAGE Therapeutics' official website?

The official website for SAGE Therapeutics is http://www.sagerx.com/.

How can I contact SAGE Therapeutics?

SAGE Therapeutics' mailing address is 215 FIRST STREET, CAMBRIDGE MA, 02142. The biopharmaceutical company can be reached via phone at 617-299-8380 or via email at [email protected]


MarketBeat Community Rating for SAGE Therapeutics (NASDAQ SAGE)

Community Ranking:  3.2 out of 5 (star star star)
Outperform Votes:  535 (Vote Outperform)
Underperform Votes:  312 (Vote Underperform)
Total Votes:  847
MarketBeat's community ratings are surveys of what our community members think about SAGE Therapeutics and other stocks. Vote "Outperform" if you believe SAGE will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SAGE will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 1/29/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel